A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2
Impact in
- Cancer Research 224
Classified as
- Journal
- Nature Medicine
In The Last Decade
doi.org/10.1038/nm846 →Countries where authors are citing A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2
This map shows the geographic impact of A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 more than expected).
Fields of papers citing A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2
This network shows the impact of A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2.
About A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2
This paper, published in 2003, received 523 indexed citations . Written by Jian Qi, Quteba Ebrahem, Nina Z. Moore, Gillian Murphy, Lena Claesson‐Welsh, Mark Bond, Andrew H. Baker and Bela Anand‐Apte covering the research area of Cancer Research, Ophthalmology and Hematology. It is primarily cited by scholars working on Molecular Biology (229 citations), Cancer Research (224 citations), Oncology (96 citations), Ophthalmology (55 citations) and Hematology (53 citations). Published in Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1038/nm846.